Why the study?
Does antiplatelet therapy improve outcomes in patients with acute stroke and postischemic stroke?
Does antiplatelet therapy improve outcomes in patients with acute stroke and postischemic stroke?
This review summarizes the role, benefits, and risks of antiplatelet therapy in the treatment and secondary prevention of ischemic stroke.
Answers are grounded in this paper and cite their sources.
Consolidates antiplatelet evidence for ischemic stroke clinicians; leaves open optimal regimens via prospective trials.
The review of literature gives current views on the role of antiplatelet therapy in the treatment and secondary prevention of ischemic stroke. Relying on the data of evidence-based medicine, the author provides analytical characteristics of all platelet antiaggregants that have been put through worldwide clinical trials. The benefits and risks of each agent are shown in both monotherapy and combination therapy. The basic principles of choice of antiplatelet drugs for patients with acute stroke and postischemic stroke are outlined.
No takes yet. Share an insight, caveat, or question.
A. V. Fonyakin (2013) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: